<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tacrolimus</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00864</strong>&#160; (APRD00276, EXPT01437)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient&#8217;s immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin <span class="caps">FKBP</span>-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00864/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00864/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00864.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00864.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00864.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00864.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00864.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00864">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Tacrolimus Hydrate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000167/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000167/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: NWJQLQGQZSIBAF-MLAUYUEBSA-N</li>
              <li>Monoisotopic Mass: 821.492541363</li>
              <li>Average Mass: 822.0334</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000167">DBSALT000167</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Advagraf </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hecoria </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prograf</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Protopic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>104987-11-3</td></tr><tr><th>Weight</th><td>Average: 804.0182<br>Monoisotopic: 803.481976677</td></tr><tr><th>Chemical Formula</th><td>C<sub>44</sub>H<sub>69</sub>NO<sub>12</sub></td></tr><tr><th>InChI Key</th><td>QJJXYPPXXYFBGM-LFZNUXCKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(prop-2-en-1-yl)-11,28-dioxa-4-azatricyclo[22.3.1.0^{4,9}]octacos-18-ene-2,3,10,16-tetrone</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Macrolide Lactams</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Macrolide Lactams</td></tr><tr><th>Alternative parents</th><td>Alpha Amino Acid Esters; Macrolides and Analogues; Cyclohexanols; Piperidines; Oxanes; Tertiary Carboxylic Acid Amides; Ketones; Hemiacetals; Tertiary Amines; Carboxylic Acid Esters; Cyclic Alcohols and Derivatives; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>cyclohexanol; piperidine; oxane; tertiary carboxylic acid amide; cyclic alcohol; carboxamide group; hemiacetal; secondary alcohol; tertiary amine; ketone; carboxylic acid ester; carboxylic acid; carboxylic acid derivative; ether; polyamine; alcohol; organonitrogen compound; amine; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the macrolide lactams. These are cyclic polyketides containing  both a cyclic amide and a cyclic ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.</td></tr><tr><th>Pharmacodynamics</th><td>Tacrolimus is a macrolide antibiotic. It acts by reducing peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This inhibits both T-lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to cyclosporine studies have shown that the incidence of acute rejection is reduced by tacrolimus use over cyclosporine. Tacrolimus has also been shown to be effective in the topical treatment of eczema, particularly atopic eczema. It suppresses inflammation in a similar way to steroids, but is not as powerful. An important dermatological advantage of tacrolimus is that it can be used directly on the face; topical steroids cannot be used on the face, as they thin the skin dramatically there. On other parts of the body, topical steroid are generally a better treatment.</td></tr><tr><th>Mechanism of action</th><td>The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.</td></tr><tr><th>Absorption</th><td>Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17&#177;10%; in adults liver transplant patients is 22&#177;6%; in healthy subjects is 18&#177;5%. The absolute bioavailability in pediatric liver transplant patients was 31&#177;24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>2.6 &#177; 2.1 L/kg [pediatric liver transplant patients]</li>
	<li>1.07 &#177; 0.20 L/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>3.1 &#177; 1.6 L/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>3.7 &#177; 4.7 L/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]</li>
	<li>3.9 &#177; 1.0 L/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>3.1 &#177; 3.4 L/kg [Severe hepatic impairment, 8 mg dose, PO]</li>
</ul></td></tr><tr><th>Protein binding</th><td>~99% bound to human plasma protein, primarily to albumin and alpha-1-acid glycoprotein. This is independent of concentration over a range of 5-50 ng/mL. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, extensive, primarily by CYP3A4. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tacrolimus</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00390">31-O-Demethyltacrolimus</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/392">Details</a></td></tr><tr><td>Tacrolimus</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00670">13-demethyl tacrolimus</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/691">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>In man, less than 1% of the dose administered is excreted unchanged in urine. When administered IV, fecal elimination accounted for 92.6&#177;30.7%, urinary elimination accounted for 2.3&#177;1.1%.</td></tr><tr><th>Half life</th><td>The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5&#177;3.8 hours, in pediatric kidney transplant patients was 10.2&#177;5.0 (range 3.4-25) hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>0.040 L/hr/kg [healthy subjects, IV]</li>
	<li>0.172 &#177;  0.088 L/hr/kg [healthy subjects, oral]</li>
	<li>0.083 L/hr/kg [adult kidney transplant patients, IV]</li>
	<li>0.053 L/hr/kg [adult liver transplant patients, IV]</li>
	<li>0.051 L/hr/kg [adult heart transplant patients, IV]</li>
	<li>0.138 &#177;  0.071 L/hr/kg [pediatric liver transplant patients]</li>
	<li>0.12 &#177; 0.04 (range 0.06-0.17) L/hr/kg [pediatric kidney transplant patients]</li>
	<li>0.038 &#177; 0.014 L/hr/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>0.042 &#177; 0.02 L/hr/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>0.034 &#177; 0.019 L/hr/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]</li>
	<li>0.017 &#177; 0.013 L/hr/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]</li>
	<li>0.016 &#177; 0.011 L/hr/kg [Severe hepatic impairment, 8 mg dose, PO]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD<sub>50</sub>=134-194 mg/kg (rat).</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Multidrug resistance protein 1<br>Gene symbol: ABCB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08183" target="_blank">P08183 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2032582" target="_blank">rs2032582 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele (G2677T)</td><td>Increased risk of neurotoxicity</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/12352921" target="_blank" title='# Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002 Aug 27;74(4):571-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12352921'>12352921 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8264</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5977</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7862</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8687</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7974</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8135</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7435</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8874</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9053</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9402</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8969</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.869</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9807</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6355
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9422
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9698
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7541 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9817
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8733
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astellas pharma us inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li>
<li>Astellas Pharma US</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astellas.com">Astellas Pharma Inc.</a></li>
<li><a href="http://www.bandbpharmaceuticals.com">B&amp;B Pharmaceuticals</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>0.5 mg, 1 mg, 3 mg, 5 mg</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>5 mg/mL</td></tr><tr><td>Ointment</td><td>Topical</td><td>0.03%, 0.1%</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00106">Abarelix</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB05773">ado-trastuzumab emtansine</a></td><td>Avoid combination due to the increase in immunosuppressant side effects.</td></tr><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00681">Amphotericin B</a></td><td>Additive renal impairment may occur during concomitant therapy with Amphotericin B. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>The protease inhibitor, Amprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Amprenavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00714">Apomorphine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB04626">Apramycin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Apramycin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01169">Arsenic trioxide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. </td></tr><tr><td><a href="/drugs/DB08870">Brentuximab vedotin</a></td><td>Avoid combination due to the potential enhancement of toxic effects of immunosuppressants.</td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00958">Carboplatin</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB00262">Carmustine</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
</td></tr><tr><td><a href="/drugs/DB00520">Caspofungin</a></td><td>Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00291">Chlorambucil</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Cimetidine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood. </td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Cisplatin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00242">Cladribine</a></td><td>Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, Clarithromycin, may also increase the blood concentration of Tacrolimus.</td></tr><tr><td><a href="/drugs/DB00631">Clofarabine</a></td><td>Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. </td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Conivaptan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01406">Danazol</a></td><td>Danazol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Danazol therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>The protease inhibitor, Darunavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Darunavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the serum concentration of tacrolimus by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tacrolimus if diltiazem therapy is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00757">Dolasetron</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01184">Domperidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Tacrolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of tacrolimus. Monitor plasma concentrations and adjust dose accordingly. </td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>Felodipine increases tacrolimus levels</td></tr><tr><td><a href="/drugs/DB01195">Flecainide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00875">Flupentixol</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, Fosamprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Fosamprenavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00529">Foscarnet</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of tacrolimus</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination due to the enhancement of side effects from immunosuppressants.

</td></tr><tr><td><a href="/drugs/DB01218">Halofantrine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB04865">Homoharringtonine</a></td><td>Avoid combination as there is potential to increase immunosuppressant adverse effects. 
</td></tr><tr><td><a href="/drugs/DB00308">Ibutilide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00808">Indapamide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00270">Isradipine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>The protease inhibitor, Lopinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Lopinavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00408">Loxapine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>Methylprednisone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Methylprednisone therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01233">Metoclopramide</a></td><td>Metoclopramide may increase the concentration of Tacrolimus in the blood. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Metoclopramide therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Metronidazole increases the levels/toxicity of tacrolimus</td></tr><tr><td><a href="/drugs/DB01388">Mibefradil</a></td><td>The calcium channel blocker, Mibefradil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Mibefradil therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Miconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00688">Mycophenolate mofetil</a></td><td>Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range.</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nefazodone therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, Nelfinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nelfinavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00994">Neomycin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Netilmicin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>The calcium channel blocker, Nifedipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nifedipine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB04868">Nilotinib</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00104">Octreotide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants.</td></tr><tr><td><a href="/drugs/DB00738">Pentamidine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00556">Perflutren</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Posaconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01599">Probucol</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Quinidine, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended. </td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Sirolimus may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Sirolimus therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB01082">Streptomycin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Streptomycin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Temsirolimus may decrease the blood concentration of Tacrolimus. Concomitant therapy may increase the adverse/toxic effects of both agents. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB08880">Teriflunomide</a></td><td>Avoid combination due to the increased toxic effects of immunosuppressants.
</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Tobramycin. Use caution during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination due to the potential increase in immunosuppressant associated adverse effects.
</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food, especially food with a high-fat content, decreases the rate and extent of absorption.</li>
<li>The time of the meal affects tacrolimus bioavailability. Take tacrolimus capsules consistently everyday either with or without food. </li></ul></td></tr></tbody></table>